Back to Search
Start Over
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
- Source :
-
Brain : a journal of neurology [Brain] 2009 Nov; Vol. 132 (Pt 11), pp. 3152-64. Date of Electronic Publication: 2009 Oct 05. - Publication Year :
- 2009
-
Abstract
- Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB(1) cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB(1) receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB(1) receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB(2) receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB(2) receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB(2) receptor-mediated actions. These findings support a pivotal role for CB(2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.
- Subjects :
- Animals
Anti-Bacterial Agents pharmacology
Biomarkers metabolism
Corpus Striatum cytology
Corpus Striatum drug effects
Corpus Striatum metabolism
Corpus Striatum pathology
Humans
Huntingtin Protein
Magnetic Resonance Imaging
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Minocycline pharmacology
Nerve Degeneration metabolism
Nerve Tissue Proteins genetics
Nerve Tissue Proteins metabolism
Nuclear Proteins genetics
Nuclear Proteins metabolism
Quinolinic Acid pharmacology
Receptor, Cannabinoid, CB2 genetics
Rotarod Performance Test
Seizures physiopathology
Huntington Disease metabolism
Huntington Disease pathology
Huntington Disease physiopathology
Microglia metabolism
Neuroprotective Agents metabolism
Receptor, Cannabinoid, CB2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1460-2156
- Volume :
- 132
- Issue :
- Pt 11
- Database :
- MEDLINE
- Journal :
- Brain : a journal of neurology
- Publication Type :
- Academic Journal
- Accession number :
- 19805493
- Full Text :
- https://doi.org/10.1093/brain/awp239